Navigation Links
Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
Date:12/14/2010

THE WOODLANDS, Texas, Dec. 14, 2010 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced top-line results from a recently completed Phase 2a study of LX2931 in patients with rheumatoid arthritis (RA).  LX2931 is an orally-delivered, small molecule drug candidate that inhibits sphingosine-1-phosphate (S1P) lyase, an enzyme important for modulating the immune system by controlling S1P levels in lymphoid tissues. The trial was the first test of this new anti-inflammatory mechanism of action in patients and was designed to obtain safety and tolerability information and signals of efficacy.  

Results from the 12-week, randomized, double-blind, placebo-controlled study in 208 patients with RA demonstrated that all three doses tested, 70 mg, 110 mg, and 150 mg given once per day, were well tolerated over the 12-week treatment period.  Taken together, the data also suggested that patients treated with 150 mg once daily of LX2931 showed an improvement in the primary efficacy endpoint, the percentage of patients achieving an American College of Rheumatology 20 (ACR20) response at week 12 (60% versus 49% for placebo).  Patients treated with 70 mg or 110 mg once daily did not indicate improvement in the ACR20 at week 12 (44% and 41% response rates, respectively) relative to placebo. Adverse events for all three LX2931 dose groups were predominantly mild-to-moderate, with frequencies similar to the placebo group.

"We believe the preliminary signal of efficacy and the favorable safety profile observed in this trial supports further study
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... N.J. , May 4, 2015 Thirty-six ... percent seek help. During May – National Hearing Month ... loss could be missing out on the sounds of ... the trees. To ensure that you won,t ... that color our world, Oticon, Inc. offers practical advice: ...
(Date:5/4/2015)... 2015  Impax Laboratories, Inc. (NASDAQ: IPXL ) ... roles, appointing  Donna M. Hughes, as Senior Vice President, ... Senior Vice President, Chief Compliance Officer. Both Ms. Hughes ... Chief Executive Officer, Fred Wilkinson . ... the Impax team," said Fred Wilkinson , President ...
(Date:5/4/2015)... Bayer HealthCare (Bayer) has entered into an ... ISIS ) on ISIS-FXI Rx, an antisense investigational ... Under the agreement Bayer will further develop and commercialize ... need. As part of the clinical development program, Bayer ... in an appropriate patient community. "Bayer ...
Breaking Medicine Technology:It's Better Hearing Month 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 3Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3
(Date:5/5/2015)... (PRWEB) May 05, 2015 Curly Hair Solutions™ ... Keeper Collection, Curl Keeper™ Beach Mist. The collection has every ... The secret to mastering those loose to medium body curls ... Curl Keeper™ Beach Mist those fancying the ocean breeze needn’t ... (and/or skin) Curl Keeper™ Beach Mist produces the same invigorating ...
(Date:5/4/2015)... Visiopharm, the leader in image analysis for diagnostic ... round of financing with NorthCap Partners . The ... Visiopharm to further accelerate business growth and strengthen their ... diagnostic digital pathology solutions. , "It has been exciting ... solution has energized the pathologists, and how fast we ...
(Date:5/4/2015)... Garden City, NY (PRWEB) May 05, 2015 ... honors Gloria M. Betancourt as a ... Year Circle. She is recognized with this prestigious distinction ... networking organization exclusively for professional women, boasting more than ... "I'm pleased to present Gloria with this important honor," ...
(Date:5/4/2015)... IOWA (PRWEB) May 04, 2015 The ... appointed Gregs G. Thomopulos, P.E., Chairman of Stanley ... (ISI) board of directors for a three-year term. ... Association (APWA) and the American Society of Civil Engineers ... a sustainability rating system for civil infrastructure called Envision. ...
(Date:5/4/2015)... In a continuing effort to remain a ... Wickstrom, the founder of Choices Recovery in South Bend, ... to the Oscars” celebration held on February 21st, ... of the luxurious Beverly Hilton Hotel. , Organized ... product placement in TV and film, this daylong event ...
Breaking Medicine News(10 mins):Health News:Curly Hair Solutions Introduces New Revolutionary Product: Curl Keeper Beach Mist 2Health News:Visiopharm Closes Investment Round to Grow Diagnostic Digital Pathology Business 2Health News:Visiopharm Closes Investment Round to Grow Diagnostic Digital Pathology Business 3Health News:National Association of Professional Women Inducts Gloria Betancourt, Receptionist at Consulate Health Care, into its 2015-2016 VIP Woman of the Year Circle 2Health News:Thomopulos Appointed to Institute for Sustainable Infrastructure Board 2Health News:Per Wickstrom Interviews TV and Film Star Carolyn Hennesy About Substance Abuse and Treatment 2
... Blank Family,Foundation today announced it is awarding $100,000 ... Foundation to fund a,comprehensive study that will explore ... Georgia,s Pre-K enrollment rates have stalled at around ... In order to improve outcomes for,children, high quality ...
... WEST LAFAYETTE, Ind. - A Purdue University researcher is working ... way that more accurately reflects real-world situations. , "The traditional ... is to put them in a quiet room and ask ... see," said Karen Iler Kirk, a professor of speech, language ...
... Healthcare, AFL-CIO Secretary Treasurer Richard Trumka to Keynote Canadian, ... ... First Responders to Join Emotional September 11th Rally With a,Plea ... OAKLAND, Calif., Sept. 6 The California Nurses,Association/National Nurses ...
... Women,s ... Cancer Research Fund, MONTVALE, N.J., Sept. ... its all-new, eagerly-awaited 2008,C350 Sport Sedan to raise funds for Saks ... partnership with the Entertainment,Industry Foundation,s (EIF) Women,s Cancer Research Fund. As ...
... of Emergency Medicine will participate in a nationwide study ... increasingly common, antibiotic-resistant infection. , The objective of ... for otherwise healthy people who have MRSA, said David ... the School of Medicine and Hospital, who will lead ...
... & Diamonds: An Evening with Tim McGraw and Friends, ... Presented by Anheuser-Busch Companies, ... its third annual fundraising gala on Friday, Nov. 2 at ... St. Louis. Anheuser-Busch,Companies is sponsoring "Denim & Diamonds: An Evening ...
Cached Medicine News:Health News:The Arthur M. Blank Family Foundation Pushes for Pre-K Expansion in Georgia 2Health News:Researcher developing new method for hearing loss assessment 2Health News:Hundreds of RNs from Across U.S. and World to Join California Nurses Association/NNOC National Convention 2Health News:Mercedes-Benz Special Edition C350 Sport Sedan to Raise $1 Million for Saks Fifth Avenue's KEY TO THE CURE 2Health News:Mercedes-Benz Special Edition C350 Sport Sedan to Raise $1 Million for Saks Fifth Avenue's KEY TO THE CURE 3Health News:Mercedes-Benz Special Edition C350 Sport Sedan to Raise $1 Million for Saks Fifth Avenue's KEY TO THE CURE 4Health News:Temple Emergency Medicine receives $1.8M to find best MRSA treatment 2Health News:Temple Emergency Medicine receives $1.8M to find best MRSA treatment 3Health News:The Tug McGraw Foundation Announces 2007 Fundraising Gala 2Health News:The Tug McGraw Foundation Announces 2007 Fundraising Gala 3Health News:The Tug McGraw Foundation Announces 2007 Fundraising Gala 4
BD Persist Plus protective barrier provides a one-step antimicrobial barrier with minimum of 1% chlorhexidine with Up to 7-day antimicrobial effectiveness....
The design of the new ChloraPrep swabstick applicator provides significant improvement in performance over traditional swabsticks....
... Swabsticks are packaged in easy open, single-use ... saturated with precisely the correct amount of ... the safest possible product for the patient. ... an excellent combination of ethyl alcohol and ...
... provides 5% povidone-iodine solution ... It delivers a microbicidal ... tender to touch. It ... indicated whenever effective microbicidal ...
Medicine Products: